Physician profile
Adrian Chan
NPI 1770758476
$2,703.51
in general payments reported to CMS, 2019-2025
13 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.71 · 2020: $118 · 2021: $13.93 · 2022: $301 · 2023: $1,135 · 2024: $643 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671 · Travel and Lodging: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.73 |
| Travel and Lodging | $588.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,210.89 | 2023-2025 | Percept Pc Brainsense |
| Eisai INC. | $304.08 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $250.44 | 2023-2024 | Ingrezza |
| Lilly USA, LLC | $244.59 | 2022-2025 | Kisunla |
| Abbott Laboratories | $231.65 | 2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $229.64 | 2020-2022 | |
| Abbvie INC. | $119.18 | 2021-2025 | Duopa |
| Allergan, INC. | $27.80 | 2022 | |
| Tanabe Pharma America, INC. | $25.74 | 2024 | |
| Acadia Pharmaceuticals INC | $17.51 | 2023 | Nuplazid |
| Mdd US Operations, LLC | $16.29 | 2024 | Gocovri |
| Sumitomo Pharma America, INC. | $13.99 | 2024 | Gemtesa |
| Biogen, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.